Veronica Rendo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3824123/publications.pdf

Version: 2024-02-01

1163117 1372567 11 303 8 10 citations h-index g-index papers 12 12 12 478 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nature Genetics, 2020, 52, 662-668.	21.4	168
2	Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer. Cancer Research, 2017, 77, 1730-1740.	0.9	29
3	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nature Communications, 2022, 13, 604.	12.8	22
4	Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine <i>N</i> â€Acetyltransferase NAT2. Angewandte Chemie - International Edition, 2020, 59, 14342-14346.	13.8	18
5	Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy. Nature Communications, 2020, 11, 1308.	12.8	18
6	Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis. Journal of Experimental and Clinical Cancer Research, 2021, 40, 225.	8.6	13
7	Somatic <i>PRDM2</i> c.4467delA mutations in colorectal cancers control histone methylation and tumor growth. Oncotarget, 2017, 8, 98646-98659.	1.8	13
8	Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer. Scientific Reports, 2020, 10, 22436.	3.3	5
9	Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine N â€Acetyltransferase NAT2. Angewandte Chemie, 2020, 132, 14448-14452.	2.0	2
10	Adding to the CASeload: unwarranted p53 signaling induced by Cas9. Molecular and Cellular Oncology, 2020, 7, 1789419.	0.7	0
11	Targeting tumor vulnerabilities associated with loss of heterozygosity. Molecular and Cellular Oncology, 2020, 7, 1759390.	0.7	O